More employers are dropping GLP-1 weight loss coverage before open enrollment
The share of employers covering GLP-1 drugs for weight management dropped from 72% in 2025 to 60% in 2026, with 14% planning to drop coverage by 2027. Starbucks confirmed it will stop covering GLP-1 medications for weight loss starting in October, citing high costs. Pharmacy costs now represent 25% of employers' total healthcare spend, with drug costs projected to rise 12%. Some employers are tightening eligibility criteria instead of dropping coverage entirely.
How this was made
The 30-second read
Why it matters
The trend may affect demand for GLP‑1 manufacturers and influence broader health‑benefit cost dynamics.
Market read
Highlights a cost‑containment shift among U.S. employers that could ripple to pharma and benefit‑cost sectors.
What to watch
Potential employee backlash or turnover if out‑of‑pocket costs rise sharply.
Background
Employers are reducing coverage of expensive GLP‑1 weight‑loss drugs as costs rise, with 14% planning to drop coverage by 2027.
Ticker impact
Starbucks will stop covering GLP-1 weight‑loss medications for eligible employees starting October.
Modest short‑term downside risk if investors view the move as a cost‑cutting signal.
The coverage change is a new corporate policy affecting a large employer; impact on stock price is likely limited but could influence sentiment around labor cost management.
Market effects
Signals tightening of employer health‑benefit spending, may pressure pharma companies selling GLP‑1 drugs.
U.S. employer benefits market sees cost‑containment trend.
Limited; primarily U.S. employer‑benefit landscape.
Counterpoint
The coverage cut could be seen as a positive cost‑control measure, supporting earnings outlook.
Key entities
- CompanyStarbucks
Large U.S. employer implementing benefit change.
- Research FirmBusiness Group on Health
Provides survey data on employer coverage trends.
